Objective. To describe systemic autoimmune joint diseases that develop following Lyme disease, and to compare their clinical features with those of Lyme arthritis (LA).
Methods. We reviewed records of all adult patients referred to our LA clinic over a 13-year period, in whom we had diagnosed a systemic autoimmune joint disease following Lyme disease. For comparison, records of patients enrolled in our LA cohort over the most recent 2-year period were analyzed. Levels of IgG antibodies to Borrelia burgdorferi and to 3 Lyme disease-associated autoantigens were measured.
Results. We identified 30 patients who had developed a new-onset systemic autoimmune joint disorder a median of 4 months after Lyme disease (usually manifested by erythema migrans [EM] ). Fifteen had rheumatoid arthritis (RA), 13 had psoriatic arthritis (PsA), and 2 had peripheral spondyloarthritis (SpA). The 30 patients typically had polyarthritis, and those with PsA or SpA often had previous psoriasis, axial involvement, or enthesitis. In the comparison group of 43 patients with LA, the usual clinical picture was monoarticular knee arthritis, without prior EM. Most of the patients with systemic autoimmune joint disorders were positive for B burgdorferi IgG antibodies, as detected by enzyme-linked immunosorbent assay, but had significantly lower titers and lower frequencies of Lyme disease-associated autoantibodies than patients with LA. Prior to our evaluation, these patients had often received additional antibiotics for presumed LA, without benefit. We prescribed antiinflammatory agents, most commonly disease-modifying antirheumatic drugs, resulting in improvement.
Conclusion. Systemic autoimmune joint diseases (i.e., RA, PsA, SpA) may follow Lyme disease. Development of polyarthritis after antibiotic-treated EM, previous psoriasis, or low-titer B burgdorferi antibodies may provide insight into the correct diagnosis.
Lyme arthritis (LA) was identified as a clinical entity in the late 1970s after an outbreak of monoarticular and oligoarticular arthritis in children in Lyme, Connecticut (1) . LA is now known to be a late manifestation of Lyme disease (2) , which is caused by the tick-transmitted spirochete Borrelia burgdorferi (3) . Before the cause of the disease was known, ;60% of patients with Lyme disease who were not treated with antibiotics developed LA, within a median duration of 6 months (range 4 days to 2 years) after the initial erythema migrans (EM) skin lesion (4) . These patients experienced intermittent or persistent attacks of swelling and pain primarily in 1 or a few large joints, especially the knee, over a period of several years (4, 5) . Small joints, tendons, or bursae were occasionally affected, usually in 1 location at a time. However, while some patients may have reported a history of a tick bite or EM, arthritis may have been the presenting manifestation of LA, without earlier signs or symptoms of Lyme disease (6) .
Serologic testing using a 2-test approach (enzymelinked immunosorbent assay [ELISA] and Western blot) is the mainstay of LA diagnosis (7) . Patients with LA typically have markedly elevated IgG antibody responses to B burgdorferi, with expansion of the response to many spirochetal proteins (8) . The majority of patients with LA respond to appropriate oral or intravenous (IV) antibiotic treatment, but some patients have persistent proliferative synovitis in previously infected joints, usually a knee, after 2-3 months of such therapy; this is termed postinfectious, antibiotic-refractory arthritis (9) . In these patients, the synovial lesion is similar in that in other forms of chronic inflammatory arthritis, including rheumatoid arthritis (RA) or psoriatic arthritis (PsA). After oral and IV antibiotic therapy, patients with antibiotic-refractory arthritis are treated with antiinflammatory agents, disease-modifying antirheumatic drugs (DMARDs), or synovectomy (6,9), analogous to treatment used for other forms of chronic inflammatory arthritis.
There is strong evidence for an immune-mediated process in patients with antibiotic-refractory LA. This outcome is associated with certain HLA-DR alleles (10), excessive joint inflammation (11) , immune dysregulation of the CD41 Teff:Treg cell ratio (12, 13) , and infectioninduced autoimmunity (14) . Immunoreactivity with spirochetal remnants may also be a factor (2) . Using mass spectrometry to identify naturally presented HLA-DR peptides in synovial tissue (15), we have now identified 4 self proteins-endothelial cell growth factor (ECGF), apolipoprotein B-100 (Apo B-100), annexin A2, and matrix metalloproteinase 10 (MMP-10). Each of these self proteins is a target of T and B cell responses in ;10-35% of patients with LA, particularly in those with antibioticrefractory arthritis (14) (15) (16) (17) (18) (19) . Moreover, in patients with antibiotic-refractory LA, the levels of anti-ECGF autoantibodies correlated with obliterative microvascular lesions in synovial tissue, suggesting that these antibodies may have pathologic potential (16) . Antibody responses to ECGF were not found in patients with other types of arthritis, and reactivity with MMP-10 and Apo B-100 were unusual in other arthritides; however, annexin A2 antibody responses occur in several rheumatic diseases (20) .
Antibiotic-refractory LA is usually confined to a previously infected joint (most commonly a knee) and is accompanied by few, if any, systemic symptoms (2,9). However, systemic autoimmune arthritides following Lyme disease are less well described. In one previous study, 9 of 51 patients presenting with reactive arthritis who lacked a clinical history of Lyme disease were found to have antibody and T cell responses to B burgdorferi antigens (21) . Although B burgdorferi antibody titers declined after antibiotic therapy, arthritis rarely resolved. The authors proposed that B burgdorferi may be among the infectious agents that trigger reactive arthritis.
This report describes a cohort of 30 patients who developed new-onset RA, PsA, or peripheral spondyloarthropathy (SpA), usually within several months after antibiotic treatment for B burgdorferi infection. Our study demonstrates that when inflammatory arthritis develops in the context of Lyme disease, clinicians need to distinguish among 3 possibilities: patients who have active infection in joints, those who have postinfectious LA, and those who have another form of inflammatory arthritis following Lyme disease.
PATIENTS AND METHODS
Patients. All medical records of adult patients (age . 18 years) seen over a 13-year period (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) in the Rheumatology Clinic at Massachusetts General Hospital (MGH) who were referred for suspected LA and in whom we had diagnosed a systemic autoimmune joint disease were reviewed. Thirty patients were identified based on the presence of a well-defined systemic autoimmune joint disease occurring within 2 years after Lyme disease diagnosis, the timeframe in which LA may develop following EM (4). The autoimmune diseases were classified according to validated criteria (22) (23) (24) . Patients presenting with systemic autoimmune joint diseases who had a positive serologic test result for Lyme disease without prior clinical symptoms of the illness were not included. Patients with nonspecific pain and fatigue syndromes following Lyme disease without evidence of objective arthritis were excluded.
For comparison, all 43 adult patients enrolled in our LA cohort study over the most recent 2-year period (2014) (2015) were analyzed. All of these patients met the diagnostic criteria of the Centers for Disease Control and Prevention (CDC) for that disease (25) . Patients with arthritis that resolved within 1 month after completion of oral or IV antibiotic therapy were defined as having antibiotic-responsive arthritis, whereas patients with arthritis that persisted longer than 1 month after completion of antibiotic therapy were classified as having post-infectious, antibiotic-refractory arthritis. The study was approved by the MGH Institutional Review Board, and written informed consent was obtained from each subject.
Clinical evaluation. Demographic data were collected and clinical histories (including history of smoking, Lyme disease, skin psoriasis, and antibiotic treatment, as well as autoimmune disease in first-degree relatives) were recorded. Swollen and tender joint counts were documented. Serum samples were obtained from each patient at the initial visit. Rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were measured in the MGH clinical laboratories.
B burgdorferi and Lyme disease-associated autoantibody testing. Serum antibodies to B burgdorferi were measured in our research laboratory by 2-tier sonicate ELISA and Western blot, as previously described (8, 26) . Testing for antibody responses to 3 Lyme disease-associated autoantigens (ECGF, Apo B-100, and MMP-10) was also performed, as previously described (14) (15) (16) (17) (18) (19) . Autoantibody testing was not done for annexin A2, which is less specific for Lyme disease. For comparison with the LA and post-Lyme disease systemic autoimmune arthritis groups, serum samples were randomly selected from 43 patients in our newonset RA cohort (27) , 21 patients with PsA or SpA (none of whom had a history of Lyme disease), and 72 healthy control subjects. A positive antibody response to each autoantigen was defined as a value of $ 3 SD above the mean in healthy controls.
Statistical analysis. For comparison of multiple groups, one-way analysis of variance (ANOVA) was performed. If significant differences were found by ANOVA, pairwise comparisons were then made. Noncategorical clinical characteristics were compared by Mann-Whitney rank sum test. Categorical variables were analyzed using Fisher's exact test. Mean antibody levels between groups were compared by Welch's unpaired t-test. All P values are 2-tailed. P values less than 0.05 were considered significant.
RESULTS
Clinical characteristics of the patients. During the 13-year period in which we have practiced at MGH, 30 patients were referred to us for evaluation of presumed LA, in whom we had diagnosed a systemic autoimmune joint disorder. Of the 30 patients (each of whom had new-onset illness) 15 had RA, 13 had PsA, and 2 had peripheral SpA. The median duration from the onset of Lyme disease to the start of joint symptoms was 4 months (range 2 weeks to 2 years) ( Figure 1 ), which is similar to the timeframe in which LA may occur after EM (4).
The number of LA patients whom we have evaluated has steadily increased over the past 13 years ( Figure 2 ). Moreover, during the most recent 3-year period, the proportion of patients in whom we diagnosed a systemic autoimmune joint disease following Lyme disease increased more than during any other period. Of the 30 patients reported here with RA, PsA, or SpA following Lyme disease, 18 (60%) were seen during the past 3 years. Overall, during this most recent period, approximately one-third of the patients referred had LA that was responsive to antibiotic therapy, another one-third had antibioticrefractory LA, and the remaining one-third had another autoimmune arthritic disorder following Lyme disease.
In Table 1 , the clinical and demographic characteristics of the 30 patients with systemic autoimmune arthritides are compared with those of the 43 patients with active infectious or postinfectious antibiotic-refractory LA. Compared with the LA group, the patients with systemic autoimmune joint disorders (particularly those with RA) were significantly older (median age 55 years versus 44 years; P 5 0.03), but similar in age to previously described early arthritis cohorts (27) (28) (29) . However, the systemic autoimmune disease group was predominantly male, which is atypical of systemic autoimmune joint diseases, particularly RA (27, 28) . There was a trend toward greater tobacco exposure in the systemic autoimmune disease group, particularly in RA patients, for whom smoking is a known risk factor (30) , though the majority of patients were nonsmokers. Patients with systemic autoimmune arthritides had significantly higher body mass index values (P , 0.0006 versus the LA group), particularly those with PsA or SpA (P , 0.0001), consistent with the high frequency of obesity as a comorbid factor in PsA (31) . Finally, the systemic autoimmune disease group was significantly more likely to have a family history of autoimmune disease in a first-degree relative than patients with LA (P 5 0.0004), particularly those with PsA or SpA.
Prior to the onset of joint symptoms, 17 of the 30 patients (57%) with systemic autoimmune joint diseases had EM skin lesions (Table 1) . Another 7 patients (23%) had signs or symptoms consistent with early disseminated Lyme disease without EM skin lesions-5 had flu-like symptoms (e.g., fever, arthralgia, neck pain) during the summer, and 2 others had manifestations of neuroborreliosis (1 each with meningitis or facial palsy). 
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In comparison, among the 43 patients in the LA group, only 2 (5%) had typical EM lesions preceding their arthritis (P , 0.0001 versus the systemic autoimmune disease group), and they did not receive antibiotic treatment at the time. An additional 7 patients (16%) recalled flu-like symptoms during the summer prior to the onset of arthritis, but did not receive antibiotics at that time. Altogether, only 9 of the 43 patients with LA had signs of early Lyme disease prior to joint involvement, compared with 24 of the 30 patients with systemic arthritis (P , 0.0001).
All 30 patients who subsequently developed systemic autoimmune joint diseases had been treated, before referral, with appropriate antibiotic regimens for Lyme disease, as recommended by the Infectious Diseases Society of America (32) . Generally, this treatment consisted of a 21-day course of oral doxycycline for early Lyme disease, but 13 of the 24 patients (54%) with signs of early Lyme disease received additional courses of oral antibiotic therapy, with a maximum treatment duration of 4 months. Five patients had previously received IV antibiotic treatment for $1 month, in most cases for later or more severe manifestations of Lyme disease (in 3 patients with LA and 1 patient with Lyme meningitis). Among the LA cohort, 35 of the 43 patients (81%) had started or completed a 30-day course of oral doxycycline prior to their referral to MGH, and the remaining 8 (19%) had also been treated with a 28-day course of IV ceftriaxone.
Features of arthritis. At the time of our evaluation, patients with systemic autoimmune joint diseases had a significantly longer duration of arthritis compared with LA patients (median 6.5 months versus 4 months) ( Table 2) . Moreover, the median duration from onset of arthritis to diagnosis of RA was 12 months, much longer than in most early RA cohorts (26, 27) . The pattern of joint involvement in the post-Lyme disease systemic autoimmune group was predominantly one of polyarthritis, which is typical of RA and PsA. Of the 15 patients with RA, 13 (87%) had symmetric polyarthritis with 5 or more joints involved (median 11 joints [range 5-27]); the other 2 patients had 3-4 joints affected. Of the 13 patients with PsA, 7 had polyarticular disease (median 9 joints [range 5-35]), while 6 had involvement of 2-4 joints. In addition, of the 15 patients with PsA or SpA, 7 patients with PsA (47%) had unique features of SpA, such as axial involvement, enthesitis, or dactylitis. The 2 patients with non-psoriatic peripheral SpA both had enthesitis and inflammatory oligoarticular arthritis. In comparison, no patients in the RA group or LA group had SpA features (P 5 0.006 and P # 0.0001, respectively, versus the PsA/SpA group). Four patients, 2 with RA and 2 with PsA, had radiographic erosions. Patients in the LA group almost always had monoarticular or oligoarticular arthritis, with a median of 1 joint affected (most commonly a knee). Only 1 patient had polyarticular involvement with 5 joints involved (bilateral knees, ankles, and 1 wrist). The majority of patients with antibiotic-refractory arthritis had persistent synovitis in previously involved joints, usually in 1 knee, but in 3 of the 24 patients, synovitis spread to 1-3 other joints during the post-antibiotic period.
Compared with patients in the LA group, the 30 patients with systemic autoimmune joint diseases usually had higher CRP values (P 5 0.02), and a trend toward higher ESR levels, particularly in the PsA/SpA group. Of the 15 RA patients, 6 (40%) had positive results for RF or ACPA, although this is a lower percentage than is usually reported in early RA cohorts (27, 28) . As expected, no patient in the PsA/SpA or LA groups had positive results for these antibodies. Of the 15 patients with PsA/ SpA, 9 (60%) had preexisting cutaneous psoriasis, but not arthritis, prior to B burgdorferi infection, whereas 4 (27%) developed both skin psoriasis and arthritis after Lyme disease. The 2 patients with non-psoriatic peripheral SpA were both negative for HLA-B27. In the LA group, 1 of the 43 patients also developed new-onset skin psoriasis following treatment for LA, but to date, this patient has not developed features of PsA.
B burgdorferi antibody responses. When seen in our clinic, 21 of the 30 patients (70%) with post-Lyme disease systemic autoimmune joint diseases had equivocal or low-positive IgG antibody responses to B burgdorferi (titer of $ 1:400) on ELISA, but only 6 patients, 4 of whom had prior LA, had positive results on Western blot. In contrast, 42 of the 43 patients with LA, including those in both the antibiotic-responsive and the antibiotic-refractory groups, had strongly positive IgG antibody responses on ELISA and Western blot, usually with reactivity with all 10 spirochetal proteins scored using the CDC criteria ( Figure 3) . The 1 patient with LA who did not meet CDC criteria had already received several courses of antibiotics, and had met CDC criteria prior to our evaluation. Thus, the magnitude of the antibody responses was significantly lower in patients with post-Lyme disease systemic autoimmune joint disorders than in those in the LA group (mean titer 1:486 versus 1:15,733; P , 0.0001) (Figure 3) . The mean levels of IgM antibodies to B burgdorferi were the same in both the systemic autoimmune and LA groups, and only 2 patients in each group had positive IgM antibody Table 1 for other definitions). (Figures 4A-C) . Of these 27 patients, 6 (22%) had positive results for 1 or more of the Lyme disease-associated autoantibodies, and 4 (15%) were positive for 2 autoantibodies (Apo B-100 and MMP-10). Of the 6 patients, 2 had RA, 3 had PsA, and 1 had SpA. In comparison, 19 of the 43 patients (44%) with LA had 1 or more of the Lyme disease-associated autoantibodies (P 5 0.08). Moreover, the levels of ECGF antibodies, the most specific of the Lyme disease-associated autoantibodies (14) , were significantly increased in both the responsive and refractory LA groups compared with the systemic autoimmune disease group (P # 0.02). The levels of MMP-10 and Apo-B 100 autoantibodies were significantly greater in the refractory versus the responsive LA group (P # 0.03), and MMP-10 levels tended to be greater than those in the systemic autoimmune joint disorder group (P # 0.1). In contrast, autoantibody positivity in the LA group and in the post-Lyme disease systemic autoimmune disease group were significantly greater than in healthy controls, or in RA or PsA/SpA patients who lacked a history of Lyme disease (only 2 of whom had borderline elevated responses). Of the 3 LA patients who experienced arthritis that spread to previously uninvolved joints in the postinfectious period, 2 had positive results on tests for MMP-10 autoantibodies, and 1 had reactivity with all 3 autoantibodies.
Treatment and outcomes. In the systemic autoimmune disease group, we advised treatment with antiinflammatory agents according to the standard of care. These treatments included steroids (3%), nonsteroidal antiinflammatory drugs (20%), DMARDs (57%) (most commonly methotrexate, but also tumor necrosis factor [TNF] inhibitors), or combinations of these agents. Arthritis was well controlled with this treatment strategy in all cases, and none of the patients had reactivation of infection. However, 6 patients (20%) were reluctant to accept the diagnosis of a systemic autoimmune disease and sought further treatment for Lyme disease elsewhere, with additional courses of antibiotic therapy.
Of the 43 LA patients, arthritis resolved within 1 month of completion of oral antibiotic treatment in 11 (26%), and in 8 patients (19%) whose arthritis did not respond to oral doxycycline, resolution occurred within 1 month of completing IV antibiotic treatment. However, 24 patients (56%) had persistent proliferative synovitis despite treatment with oral and IV antibiotics. Of these 24 patients, 23 (96%) were treated with DMARDs, including hydroxychloroquine, methotrexate, or TNF inhibitors. Similar to the systemic autoimmune disease group, these 24 patients had marked improvement within months, and to date, none has had recurrence of Lyme disease or required synovectomy.
DISCUSSION
In this study, we observed 30 patients with newonset systemic autoimmune joint disease, including RA, PsA, or peripheral SpA, that developed a median of 4 months after Lyme disease (especially after early-stage infection). We have seen increasing numbers of such cases, particularly in the last 3 years, which now constitute approximately one-third of the patients referred to us for presumed LA. Since the incidence of Lyme disease is increasing dramatically in the US (with an estimated 300,000 new cases annually) (33), more rare manifestations of the disease, including postinfectious complications, may be increasing. It is important for clinicians to be aware that a spectrum of infectious and autoimmune joint disorders may occur within the context of Lyme disease-patients may have active B burgdorferi infection in joints, antibiotic-refractory Lyme synovitis, or another form of autoimmune arthritis following Lyme disease.
The occurrence of RA, PsA, or SpA following soon after Lyme disease may simply be a coincidence, as these autoimmune disorders are relatively common and Lyme disease is epidemic in our geographic area. In Olmsted County, Minnesota, from 1955 to 2007, the annual incidence of new RA cases was 0.04% (34) . In contrast, of the 77 new adult patients we saw in 2015 who had any manifestation of Lyme disease, 6 had post-Lyme RA, PsA, or SpA (8%). However, because we are a referral center for LA, our study was not population based; this makes it difficult to compare these percentages.
Another possible explanation for the differences in incidence of RA, PsA, or SpA between our study and population-based studies (34) is that the adjuvant effect of infection may convert the preclinical phase of autoimmune disease to active arthritis. During preclinical phases, autoantibodies (or, in the case of PsA, skin psoriasis) may be present years prior to arthritis (35) (36) (37) (38) . Numerous infections have been hypothesized to serve as triggers for initiating clinical expression of RA or PsA (39) (40) (41) (42) (43) (44) (45) . In addition to antigen-specific activation of lymphocytes, microbes can provide the secondary signal necessary for the induction of a pathogenic autoimmune response, referred to as the adjuvant effect of the infection (46) . In our patients, the delay of months between the infection and systemic autoimmune disease may reflect the time needed for affinity maturation or epitope spreading of autoimmune responses. Although spirochetal infection itself may be a trigger, perturbations in the microbiome resulting from antibiotic treatment of B burgdorferi infection could also be a mechanistic factor (47) . Additionally, it is intriguing that psoriasis may follow EM (the initial lesion of Lyme disease), which may have a direct effect on the skin and its microbiome in addition to effects of antibiotic treatment.
Although other infections may trigger autoimmunity, Lyme disease is uniquely characterized by joint manifestations in its late infectious and postinfectious stages (2,6) which, along with the presence of B burgdorferi antibodies, may persist for years after resolution of infection (48) , create diagnostic confusion, and delay diagnosis and initiation of appropriate antiinflammatory therapies. However, as described here, infectious or postinfectious LA can usually be distinguished from systemic autoimmune joint diseases by numerous clinical and laboratory features. First, LA is typically characterized by monoarticular or oligoarticular involvement of large joints, and antibioticrefractory arthritis generally affects 1 large joint (most commonly a knee) in which resolution does not occur with antibiotic treatment. In contrast, systemic autoimmune joint diseases usually cause polyarthritis or may also have features of SpA. Second, in the present study, patients with systemic autoimmune disease had significant enrichment of typical risk factors, such as family history of autoimmunity, or obesity. Third, patients with systemic arthritis were much more likely to have had EM that had been treated appropriately with antibiotics. Such therapy would abort the development of subsequent LA. In contrast, in most patients with LA, joint involvement was the presenting manifestation of the disease, and none received antibiotic therapy prior to the development of arthritis. Thus, it is very unlikely that patients who develop polyarthritis after antibiotic-treated EM would have LA.
We also used laboratory tests (which are not yet available commercially) that help with analyzing these distinctions, including tests for antibody titers to B burgdorferi and Lyme disease-associated autoantibodies. Most importantly, while patients with systemic autoimmune diseases following infection may have tested positive for B burgdorferi antibodies on ELISA, they usually had only low levels of IgG antibodies to the spirochete, whereas patients with LA generally have the highest antibody titers seen among patients with the infection (8) . Additionally, of the 4 known Lyme disease-associated autoantibodies, the responses to 3 of them (ECGF, Apo B-100, or MMP-10) have reasonable specificity for LA (14, 17, 19) . However, since Lyme disease-associated autoantibodies may develop early in the illness, results of these tests may still be positive (albeit at lower titers) when patients develop other types of arthritis following 200 ARVIKAR ET AL Lyme disease, limiting their diagnostic utility in these cases. Yet, the list of known autoantibodies in Lyme disease is presumably incomplete, as only half of patients with antibiotic-refractory LA had 1 or more of these autoantibody responses. Further, while these autoantibodies have histopathologic correlations in LA, it is not clear whether they have any pathologic role in post-Lyme RA, PsA, or SpA. Thus, as knowledge of Lyme disease-specific autoimmune responses increases, these tests may become more beneficial for differential diagnosis.
Although there are many distinguishing features between postinfectious LA and systemic autoimmune arthritis, there are patients in whom the distinction may be difficult. Any of the systemic autoimmune diseases may begin with oligoarticular involvement. Six of our patients had monoarthritis of a hip or knee, which might have been the beginning of a systemic autoimmune disease, followed by the development of polyarthritis. However, the expanded antibody response to B burgdorferi and apparent response of the monoarthritis to antibiotics suggested that this initial event was LA.
Moreover, several additional observations raise the question of whether the far end of the spectrum of antibiotic-refractory LA may include the development of symmetric polyarthritis. First, in a few patients in the LA comparison group, the spread of synovitis to other joints occurred in the post-antibiotic period. Second, the majority of patients diagnosed here with post-Lyme RA lacked RF or ACPA, and 2 such patients had Lyme diseaseassociated autoantibodies. Finally, although long-term follow-up information is not available for all patients, we are aware of 4 subjects (2 with RA and 2 with PsA/SpA) who attained drug-free remission, which is atypical in these conditions, but characteristic of LA.
Regardless of whether the occurrence of systemic autoimmune joint disease following infection is coincidental, induced nonspecifically by adjuvant effects of infection, or related to specific Lyme disease-associated autoimmune responses, an important point for clinicians is that postinfectious joint disorders that occur after recommended antibiotic treatment for Lyme disease should be treated with DMARDs (rather than with additional antibiotic). Some of our patients were reluctant to accept the non-Lyme disease diagnosis and pursued further antibiotic treatment elsewhere. One patient who developed RF-and ACPApositive RA initially had complete remission of RA with methotrexate treatment, but stopped this medication and sought further treatment for Lyme disease elsewhere with prolonged courses of multiple antibiotics. Three years later, he returned in a wheelchair and had developed radiographically evident erosions, and deformities and contractures in multiple joints. Given a choice between LA and a chronic illness that may require lifelong immunosuppressive therapy, it is not surprising that patients would find LA a more attractive diagnosis. However, there is increasing evidence that earlier aggressive treatment of inflammatory arthritis is associated with improved radiographic outcomes and chances of sustained remission (49, 50) . Delaying appropriate DMARD treatment of autoimmune joint disorders, by pursuing further therapy with antibiotic agents, may lead to poorer clinical outcomes.
